A novel melanoma gene (MG50) encoding the interleukin 1 receptor antagonist and six epitopes recognized by human cytolytic T lymphocytes.
We identified a novel 8.1-kb human melanoma gene, MG50, derived from subtractive hybridization with a squamous lung carcinoma cell line, LU-1. 6.8 kb containing an open reading frame were sequenced, and the structure of the encoded 1496 amino acid protein was deduced. With HLA-A2.1-transduced Drosophila cells as antigen-presenting cells, we identified six epitopes restricted by HLA-A2.1 that elicited CTLs in vitro. Reactivity of the CTLs to melanoma cells containing MG50 indicated that the epitopes were displayed naturally. Significant cross-reactivity of CTLs immunized against a melanoma cell line that lacked HLA-A2.1 indicated that at least four of the epitopes were also recognized in a different HLA class I context, most likely HLA-A*6802. By quantitative reverse transcription, MG50 message was found in one of two skin melanoma cell lines, an ocular melanoma cell line, two of four metastatic skin melanomas, two of three mammary carcinomas, one of two colon carcinomas, and an ovarian carcinoma. Of six normal tissues, MG50 was found only in a specimen of normal skin and was absent from a congenital nevus. It is likely that MG50 is the gene for the interleukin 1 receptor antagonist because a reported sequence of cDNA from the latter had a sequence of 528 bases in the 3' region, a long contiguous base sequence, and 176 encoded amino acids identical with those of MG50. MG50 is one of the few melanoma-associated antigens that is not a differentiation antigen or a mutated protein. Because of its nature, it may prove to be important in the pathogenesis of the tumors in which it is found, as well as an immunogen and target for immunotherapy.
Mitchell
M S
MS
Center for Biological Therapy and Melanoma Research, University of California, San Diego, La Jolla 92093, USA. mitchell@karmanos.org
Kan-Mitchell
J
J
Minev
B
B
Edman
C
C
Deans
R J
RJ
D000595:Amino Acid Sequence; D000951:Antigens, Neoplasm / Q000235:genetics* / Q000276:immunology; D001483:Base Sequence; D018984:Epitopes, T-Lymphocyte / Q000235:genetics* / Q000276:immunology; D015789:HLA-A2 Antigen / Q000276:immunology; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D008545:Melanoma / Q000235:genetics* / Q000276:immunology; D058950:Melanoma-Specific Antigens; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology; D016366:Open Reading Frames; D010544:Peroxidases; D017433:Protein Structure, Secondary; D017472:Receptors, Interleukin-1; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012795:Sialoglycoproteins / Q000235:genetics* / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured; D000097423:Peroxidasin
D000951:Antigens, Neoplasm; D018984:Epitopes, T-Lymphocyte; D015789:HLA-A2 Antigen; D053590:Interleukin 1 Receptor Antagonist Protein; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D010544:Peroxidases; D017472:Receptors, Interleukin-1; D012795:Sialoglycoproteins; C507763:IL1RN protein, human; C535215:PXDN protein, human; D000097423:Peroxidasin